Amgen Inc. (AMGN)
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen Inc. (AMGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amgen Inc. (AMGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?
Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN | AMGN Price Prediction) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Amgen's Q1 Earnings Top Estimates, 16 Drugs Deliver Double-Digit Gains
AMGN beats Q1 estimates as 16 drugs post double-digit growth, offsetting biosimilar erosion and weaker legacy products while lifting 2026 outlook.
Amgen Inc. (AMGN) Q1 2026 Earnings Call Transcript
Amgen Inc. (AMGN) Q1 2026 Earnings Call Transcript
Amgen (AMGN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amgen (AMGN) Q1 Earnings and Revenues Beat Estimates
Amgen (AMGN) came out with quarterly earnings of $5.15 per share, beating the Zacks Consensus Estimate of $4.73 per share. This compares to earnings of $4.9 per share a year ago.
Amgen to Report Q1 Earnings: Can It Keep the Beat Streak Alive?
Amgen heads into Q1 earnings with growth from key drugs offset by pricing pressure, patent losses, and biosimilar competition.
FDA proposes to withdraw Amgen's rare autoimmune disease drug
The U.S. Food and Drug Administration's Center for Drug Evaluation and Research on Monday proposed withdrawing approval of Amgen's drug for a group of rare autoimmune diseases, citing a lack of proven effectiveness and untrue statements in the application that led to its approval.
Exploring Analyst Estimates for Amgen (AMGN) Q1 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Amgen (AMGN) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade
Amgen (AMGN) closed the most recent trading day at $344.55, moving 1.17% from the previous trading session.
